LillyDirect Self-Pay Pricing in 2026: Zepbound and Mounjaro Direct-to-Consumer Costs

LillyDirect is Eli Lilly's direct-to-patient pharmacy platform, launched in 2023 and significantly expanded in 2024 and 2025. By selling branded tirzepatide directly to patients without routing through a pharmacy benefit manager (PBM), Lilly can offer Zepbound and Mounjaro at prices substantially below the wholesale acquisition cost (WAC). Two molecules share the same active ingredient: Mounjaro is FDA-approved for type 2 diabetes mellitus (NDA 215866, approved May 2022), and Zepbound is FDA-approved for chronic weight management and moderate-to-severe obstructive sleep apnea (NDA 217806, approved November 2023 for obesity; OSA indication added December 2024). Both are once-weekly subcutaneous injections delivered via KwikPen or single-dose vial, and both are classified as GIP/GLP-1 dual receptor agonists, a mechanism that targets two hormonal pathways simultaneously rather than only GLP-1 as semaglutide does.

LillyDirect's self-pay pricing model addresses a critical affordability gap. Without insurance, Zepbound's WAC is $1,086 per month and Mounjaro's WAC is $1,079.77 per month at retail pharmacies. The LillyDirect Self Pay Journey Program cuts Zepbound to $299 per month at the starter dose and caps maintenance doses at $449 per month when you meet the 45-day refill requirement. For Mounjaro, LillyDirect charges a flat $499 per month for all dose strengths, representing about a 54 percent discount off list price. Crucially, neither the Zepbound nor the Mounjaro self-pay program can be used by patients who have active commercial insurance, Medicare, or Medicaid coverage. Patients with coverage must use their formulary benefit or the Mounjaro Savings Card ($25 per month for commercially insured with a type 2 diabetes prescription) or the Zepbound Savings Card ($25 per month for commercially insured, expiring December 31, 2026). For context on Medicare's GLP-1 drug coverage see does Medicare cover Zepbound and does Medicare cover Mounjaro.

The coverage landscape for tirzepatide shifted materially in 2026. Eli Lilly reached an agreement with the U.S. government announced in 2026 to expand access to obesity medicines through Medicare and Medicaid. Under that agreement, Medicare beneficiaries can access Zepbound for obesity at a $50 per month copay through the CMS Medicare GLP-1 Bridge demonstration program, beginning July 1, 2026 and running through December 31, 2027. Mounjaro remains covered by most Medicare Part D plans for type 2 diabetes with the standard 2026 Part D annual out-of-pocket cap of $2,100 under the Inflation Reduction Act. The Inflation Reduction Act did not select tirzepatide for Round-1 price negotiation (effective 2026-01-01). Semaglutide products (Ozempic, Wegovy, Rybelsus) were selected for Round-2 negotiation, with negotiated prices expected in 2027. Tirzepatide may be considered for future negotiation rounds. Medicaid coverage for tirzepatide for obesity varies by state; coverage for type 2 diabetes is generally available at state formulary copays of $1 to $8.

What LillyDirect Self-Pay Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same lillydirect self-pay can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Tirzepatide (Zepbound and Mounjaro) is a self-administered once-weekly subcutaneous injection intended for outpatient use. Patients inject it at home from a KwikPen or single-dose vial, so it almost never appears on an inpatient hospital bill as an active treatment. When tirzepatide does appear on a hospital bill, it is typically as a continuation of an outpatient regimen during a hospital admission, not as a medication administered by clinical staff. In that scenario, hospitals apply their standard pharmaceutical acquisition markup. Even a modest markup on the $1,080 list price can produce a hospital charge of $1,500 or more for a single pen.

The more consequential pricing gap for tirzepatide patients is between the retail list price and the LillyDirect direct-to-patient channel. Pharmacy benefit managers (PBMs) negotiate confidential rebates with manufacturers, but those rebates rarely flow to the patient at the pharmacy counter. A patient who fills a tirzepatide prescription at a major chain pharmacy without insurance faces the full WAC of $1,080 to $1,086 per month. PBMs profit from the spread between the negotiated net price and the list price. By selling through LillyDirect and bypassing the PBM layer, Lilly can pass savings directly to patients at $299 to $499 per month, depending on the drug and dose. This is the real-world 'markup' story for tirzepatide: not hospital markups, but the PBM spread that LillyDirect was specifically designed to circumvent.

Patients who receive an unexpectedly high hospital or pharmacy bill for tirzepatide should verify three things: first, that the correct brand name and NDC code appear on the bill (Mounjaro NDC versus Zepbound NDC have different coverage rules); second, that a prior authorization was correctly submitted and approved; and third, that no double-billing occurred for multi-dose supplies. Using the Medical Bill Analyzer can help identify overcharges before paying.

Patient Assistance Programs

Eli Lilly operates two types of programs to reduce patient out-of-pocket costs for tirzepatide, but coverage and eligibility differ substantially between Zepbound (obesity/OSA indication) and Mounjaro (type 2 diabetes indication). No income-based patient assistance program exists for Zepbound. The Lilly Cares Foundation patient assistance program covers Mounjaro only, and the LillyDirect Self Pay Journey Program is the primary affordability channel for Zepbound patients without insurance. Manufacturer coupon cards (savings cards) require active commercial insurance and are barred for Medicare, Medicaid, TRICARE, and VA patients under the federal anti-kickback statute (42 U.S.C. Section 1320a-7b).

Medicare Part D

Medicare Part D coverage for tirzepatide depends on which drug is prescribed and for which indication. Mounjaro (tirzepatide for type 2 diabetes) is covered by most Medicare Part D plans. Patients with Medicare Part D coverage for Mounjaro benefit from the 2026 annual out-of-pocket cap of $2,100 under the Inflation Reduction Act, which replaced the old catastrophic coinsurance phase. Once you reach $2,100 in combined Part D out-of-pocket spending for the year, covered drugs including Mounjaro cost $0 for the remainder of the year. Medicare covers Mounjaro for type 2 diabetes only; it does not cover tirzepatide when prescribed for weight loss alone.

Medicare Part D covers Zepbound when prescribed for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, a coverage pathway created by the FDA's OSA approval in December 2024. The OSA diagnosis code G47.33 must appear on the prescription and pharmacy claim. Starting July 1, 2026, the CMS Medicare GLP-1 Bridge demonstration program extends Part D coverage to Zepbound KwikPen for an obesity-only diagnosis at a monthly copay of $50, running through December 31, 2027. Medicare beneficiaries cannot use the LillyDirect self-pay price or the Zepbound Savings Card as alternatives or supplements to Medicare coverage. These programs are legally separate from Medicare by anti-kickback statute. The Medicare Prescription Payment Plan, available since 2025, allows Part D beneficiaries to spread out-of-pocket costs evenly across the year rather than paying large amounts in a single month.

Tirzepatide (both Mounjaro and Zepbound) was NOT selected for the first round of Medicare drug price negotiation under the Inflation Reduction Act. The Round-1 negotiated Maximum Fair Prices took effect January 1, 2026 for ten drugs including Eliquis, Jardiance, and Januvia. Semaglutide-based drugs (Ozempic, Wegovy, Rybelsus) were selected for Round-2 negotiation, with negotiated prices expected in 2027. Tirzepatide is not currently on a confirmed Round-2 list. Patients seeking the lowest Medicare Part D cost for Mounjaro should confirm their plan's formulary tier and whether a step therapy requirement applies before filling. Prior authorization is standard for both drugs under most Medicare Part D plans.

Common LillyDirect Self-Pay Billing Errors

Tirzepatide billing errors arise from the complexity of managing two brand names, two coverage indications, and multiple pricing channels. Watch for these issues before paying any Mounjaro or Zepbound bill in 2026:

• Wrong brand name billed: Mounjaro and Zepbound have different NDC codes and different formulary tier placements even though they contain the same molecule. Billing Mounjaro for an obesity diagnosis (or Zepbound for a diabetes diagnosis) will cause a denial. Confirm that the brand name on the claim matches the indication and ICD-10 code.
• Prior authorization not submitted or approved before fill: most commercial insurance plans and Medicare Part D plans require prior authorization (PA) for both Mounjaro and Zepbound. Filling without an approved PA results in a full retail charge to the patient. Verify PA approval before picking up the prescription.
• LillyDirect self-pay price applied to an insured patient: the LillyDirect Self Pay Journey Program ($299 to $499 per month) is for cash-pay patients only. Patients with active insurance cannot use this channel; they must use their plan copay plus savings card. Attempting to use both will result in a rejection at the LillyDirect pharmacy.
• Zepbound GLP-1 Bridge copay applied to single-dose vials: the Medicare GLP-1 Bridge $50 copay program starting July 1, 2026 covers only the Zepbound KwikPen formulation. Single-dose vials are excluded. If the prescription is written for vials, the GLP-1 Bridge will not apply and the standard formulary copay or full cost may be charged.
• Charged above the $2,100 annual Part D out-of-pocket cap: once you have paid $2,100 in total Part D drug out-of-pocket costs in 2026, all covered drugs including Mounjaro should cost $0 for the rest of the calendar year. If you are still being charged a copay after hitting this threshold, the pharmacy may not have your accurate claim history on file. Ask them to reprocess through your Part D plan.
• Savings card expired or rejected: the Zepbound Savings Card for commercially-insured patients expires December 31, 2026. Claims processed in 2027 will not receive the $25 copay without a new program issuance from Lilly. Check lilly.com for any 2027 savings card renewal before January 1, 2027.

Frequently Asked Questions